Investment Memo

Sahel Diagnostics

Aisha Diallo (@aisha_dx) · Low-compute AI triage for maternal health in low-resource clinics.

WATCHSignal → decision: 22h

Trust Ledger

1 verified1 claimed0 contradicted

Every claim in this memo, checked against how well it holds up.

Company Snapshot

What the company does and where it sits in the market.

Sahel Diagnostics operates in Health AI (Dakar, SN, Pre-seed). Low-compute AI triage for maternal health in low-resource clinics. Under-served maternal-health AI with grant and payer tailwinds.

Investment Hypotheses

The core bets underlying this memo, each traced to its evidence.

Team quality: Strong clinical-ML substance; under-rated by naive scoring on English fluency — corrected by the legibility engine.^{⟦ev-ad-paper⟧}
Market wedge: Under-served maternal-health AI with grant and payer tailwinds.
Traction signal: Clinic pilot started (1 site)CLAIMED
Defensibility: Idea survives; distribution in low-resource settings is the real challenge.
Founder credibility: First-author maternal-health ML paper^{⟦ev-ad-paper⟧}VERIFIED

SWOT

Strengths, weaknesses, opportunities, threats — shown only where evidence exists.

Strengths

Delegate-an-Analyst: Caught the planted error and rewrote the market-size line herself.
First-author maternal-health ML paper^{⟦ev-ad-paper⟧}VERIFIED

Opportunities

Founder axis improving: Strong clinical-ML substance; under-rated by naive scoring on English fluency — corrected by the legibility engine.^{⟦ev-ad-paper⟧}
Market axis improving (bullish): Under-served maternal-health AI with grant and payer tailwinds.
arXiv First-Author Signal: Surfaced via a cited maternal-health ML paper with a productizing repo.

Threats

Steelman-Your-Rival: Solid on clinical rigor but under-mapped the distribution incumbents.

Problem & Product

The problem being solved and how the product addresses it.

Problem: Under-served maternal-health AI with grant and payer tailwinds.

Product: Low-compute AI triage for maternal health in low-resource clinics. Idea survives; distribution in low-resource settings is the real challenge.

Traction & KPIs

Traction and revenue signals, with unverified gaps flagged explicitly.

Clinic pilot started (1 site)CLAIMED — Early; single-site, self-reported.
ARR: not applicable — pre-revenue stage
Cap table: not disclosed
Financials / P&L: unavailable at this stage

1 sourcebehind the citations above — duplicates the inline ⟦refs⟧, expand to inspect the raw excerpt.

Three-Axis Verdict

never averaged

Founder, market, and idea-fit scored independently — one weak axis can't be masked by a strong one.

Founder

72improving

Market

63improving

BULLISH

Idea × Market

66stable

Strong substance and a real cold-start signal; advance pending a clearer distribution plan.

The Closer

$100K Check

The investment decision itself — deploy, hold, or decline — with every number traced to a receipt.

Maschmeyer Group2026-07-22

Pay to the order of

Aisha Diallo / Sahel Diagnostics

$100,000

One Hundred Thousand Dollars

Memo · Pre-seed · Maschmeyer Group

Held — pending one signal: Strong substance and a real cold-start signal; advance pending a clearer distribution plan.

Evidence trace

Armed and waiting — receipts surface the moment you deploy.

PROOF ENGINE · STANDBY